DR. GARRETT EDWARD BERGMAN, M.D.
Medical Practice at Shirley Rd, Penn Valley, PA
License number
Pennsylvania MD012124E
Category
Medical Practice
Type
Pediatric Hematology-Oncology
Address
Address
9 Shirley Rd, Penn Valley, PA 19072
Phone
(610) 667-4796
(610) 667-1986 (Fax)
(610) 664-3218
(610) 664-7442 (Fax)
(610) 667-1986 (Fax)
(610) 664-3218
(610) 664-7442 (Fax)
Personal information
See more information about GARRETT EDWARD BERGMAN at radaris.comName
Address
Phone
PO Box 465, Narberth, PA 19072
Merion Station, PA
9 Shirley Rd, Narberth, PA 19072
105 Bala Ave, Bala Cynwyd, PA 19004
500 Arcola Rd, Collegeville, PA 19426
Professional information
See more information about GARRETT EDWARD BERGMAN at trustoria.com
Dr. Garrett E Bergman, Narberth PA - MD (Doctor of Medicine)
Dr. Garrett E Bergman, Narberth PA - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Address:
9 Shirley Rd, Narberth 19072
(610) 667-4796 (Phone), (610) 667-1986 (Fax)
(610) 667-4796 (Phone), (610) 667-1986 (Fax)
Certifications:
Pediatric Oncology & Pediatric Hematology, 1976, Pediatrics, 1974
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Thomas Jefferson University
Graduated: 1969
St Christophers Hospital For Children
Thomas Jefferson University
Graduated: 1969
St Christophers Hospital For Children
Methods Of Administering Porcine B-Domainless Fviii
Methods Of Administering Porcine B-Domainless Fviii
US Patent:
8101718, Jan 24, 2012
Filed:
Jul 1, 2009
Appl. No.:
12/496516
Inventors:
John S Lollar - Decatur GA, US
Garrett E. Bergman - Narberth PA, US
Garrett E. Bergman - Narberth PA, US
Assignee:
Emory University - Atlanta GA
Ipsen Biopharm Limited - Wrexham
Ipsen Biopharm Limited - Wrexham
International Classification:
A61K 38/00, A61K 38/37
US Classification:
530383, 530350, 514 2, 514 12, 424 91
Abstract:
The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively.
Method Of Administering Porcine B-Domainless Fviii
Method Of Administering Porcine B-Domainless Fviii
US Patent:
8501694, Aug 6, 2013
Filed:
Jan 23, 2012
Appl. No.:
13/356437
Inventors:
John S. Lollar - Decatur GA, US
Garrett E. Bergman - Narberth PA, US
Garrett E. Bergman - Narberth PA, US
Assignee:
Emory University - Atlanta GA
Baxter International Inc. - Deerfield IL
Baxter Healthcare SA - Glattpark (Opfikon)
Baxter International Inc. - Deerfield IL
Baxter Healthcare SA - Glattpark (Opfikon)
International Classification:
A61K 38/37, A61P 7/04
US Classification:
514 141, 530383
Abstract:
The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively.
Method Of Administering Porcine B-Domainless Fviii
Method Of Administering Porcine B-Domainless Fviii
US Patent:
2007017, Jul 26, 2007
Filed:
Oct 12, 2006
Appl. No.:
11/549049
Inventors:
John Lollar - Decatur GA, US
Garrett Bergman - Narberth PA, US
Garrett Bergman - Narberth PA, US
International Classification:
A61K 38/37
US Classification:
514012000
Abstract:
The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively.